Insurers decline to cover Biogen's new Alzheimer's disease (AD) drug as the fallout continues from the FDA's controversial approval

July 19, 2021 | News Commentary

Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross...